PER® International Symposium on Melanoma and Other Cutaneous Malignancies
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Related Articles
Everolimus Plus Lanreotide Extends PFS in Advanced GEP-NETs
Everolimus plus lanreotide demonstrated an improved PFS compared with everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer
Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.
Real-World Use of Tafasitamab Supports Clinical Benefit in Relapsed, Refractory DLBCL | Blood Cancers Today
Tafasitamab achieved a real-world overall response rate of 73.5%, with a median duration of response of 9.6 months.
IMM-1-104 Plus Chemo Generates Responses in First-Line Pancreatic Cancer
First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.
Health Canada Green Lights Fruquintinib for Metastatic Colorectal Cancer
Health Canada approved fruquintinib for select patients with metastatic colorectal cancer.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
FDA Grants Breakthrough Device Designation to DCISionRT for Breast Cancer With DCIS
The FDA has granted a breakthrough device designation to the DCISionRT test for patients with breast cancer with ductal carcinoma in situ.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.